HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Appropriators Stoke Flames For FDA Regulation On CBD In Supplements

Executive Summary

House Appropriations subcommittee with FDA oversight makes clear in questions for Commissioner Gottlieb they support allowing use of constituent ingredients from hemp and cannabis plants in food and dietary supplement products. Members also press for approving US firms' applications for pharmaceuticals with cannabis-derived active ingredients. Gottlieb announces working group will guide FDA decisions on potential CBD-use rulemaking.


You may also be interested in...



Safe Level For CBD As Dietary Ingredient? FDA Continues Data Review

Associate commissioner Lowell Schiller's comments at recent trade group regulatory conference mark agency's first public statement on likely direction on CBD's use in food, supplements. Potentially allowing CBD's use also is making FDA "think about whether we have the tools and resources we need to take this on," Schiller said.

Allowing CBD Use In Supplements Benefits Drug Innovation – Trade Groups

Developing rules for using CBD in supplements will prevent pharma industry from creating “sweeping monopoly” over the ingredient, CRN says. CHPA says FDA's existing NDA process is appropriate not only for Rx drugs containing CBD, but also for OTC products. NPA supports allowing an exemption for CBD in supplements by establishing a daily exposure level for a healthy population through a Health Hazard Evaluation.

With Another Warning, FDA Pledges Report On CBD Use In Non-drug Products

CBD claim warning comes as FDA reviews more than 4,200 comments on its initiative to determine whether to open regulatory paths for firms to market non-drug products containing hemp- or cannabis-derived ingredients. From Deputy Commissioner Abernethy statement included in announcement about warning, it appears agency is getting message industry trade groups stated in comments that enforcement over non-drug products containing CBD cannot wait.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel